Remygen is under clinical development by Diamyd Medical and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Remygen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Remygen overview
Remygen is under development for the treatment of type 1 diabetes, type 2 diabetes and rheumatoid arthritis. It is administered through oral route as a controlled release tablet. It consists of the active pharmaceutical ingredient GABA. The drug candidate acts by targeting gamma-aminobutyric acid (GABA) receptor.
Diamyd Medical overview
Diamyd Medical (Diamyd), formerly Diamyd Therapeutics, is a drug development company that offers diabetes vaccines. The company’s diabetes products include Diamyd and Remygen. The company product Diamyd is antigen-based immunotherapy. Its other product includes remygen is a regenerative and immunomodulatory therapy. The company products are used for the treatment of autoimmune diabetes. Its products are in the clinical stage, Diamyd is at III stage and remygen is at II stages of development. The company drug has to pass several development stages such as preclinical and clinical phases. It does clinical trials of rugs in its facilities in Stockholm and umea, Sweden. Diamyd is headquartered in Stockholm, Sweden.
For a complete picture of Remygen’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.